Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled trial of foscenvivint in decompensated cirrhosis due to HCV, HBV, or NASH
jRCT2031230195Phase 2Recruiting
- Sponsor
- Ohara Pharmaceutical Co., Ltd.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of foscenvivint in decompensated cirrhosis, Hepatitis C-related cirrhosis, Cirrhosis and 1 more (5 cohorts), sponsored by Ohara Pharmaceutical Co., Ltd. Primary endpoint: Child-Pugh score. Started Oct 2023; status: recruiting.
02
Drugs
foscenvivint
03
Conditions
decompensated cirrhosisHepatitis C-related cirrhosisCirrhosiscirrhosis due to nonalcoholic steatohepatitis
Beyond the preview
Go deeper on jRCT2031230195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230195.